Chris Tovey compensation by year
Jazz Pharmaceuticals Summary Compensation Table · the one fiscal year held| Component | FY2021 |
|---|---|
| Salary | $366,576 |
| Bonus | $297,567 |
| Stock awards | $3,287,387 |
| Option awards | $0 |
| Non-equity incentive | $211,782 |
| Pension and deferred compensation | $0 |
| All other | $4,689 |
| Total | $4,168,001 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Jazz Pharmaceuticals plc DEF 14A filed June 13, 2022, accession 0001193125-22-172177, and prior-year filings.
How this page was built: the Jazz Pharmaceuticals plc filed document, accession 0001193125-22-172177. Every figure is read from that document and cited to the page and table it appears in. Filed June 13, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 9,091 | $1,158,193 | — |
| RSU | 9,090 | $1,158,066 | — |
| Option | 8,063 | — | $0.02 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Jazz Pharmaceuticals plc's FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Jazz Pharmaceuticals’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Bruce Cozadd | Chairperson and CEO | $15,679,311 |
| Daniel Swisher Jr. | President | $5,403,892 |
| Renée Galá | Executive Vice President and CFO | $4,605,224 |
| Chris Tovey · this page | Executive Vice President and Chief Operating Officer and Managing Director, Europe and International | $4,168,001 |
| Robert Iannone | Executive Vice President, Global Head of Research and Development | $4,001,336 |
| Kim Sablich | Executive Vice President and General Manager, US | $3,947,509 |
The full Jazz Pharmaceuticals compensation record
free company briefThis page is one person within Jazz Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Jazz Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Jazz Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.